| | |
| Clinical data | |
|---|---|
| Other names | 2,3,6-TMA; TMA-5 |
| Routes of administration | Oral [1] [2] |
| Drug class | Serotonergic psychedelic; Hallucinogen; Stimulant |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 8–10 hours [1] [2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C12H19NO3 |
| Molar mass | 225.288 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
2,3,6-Trimethoxyamphetamine (2,3,6-TMA), also known as TMA-5, is a psychedelic drug and mild stimulant of the phenethylamine and amphetamine families. [1] [2] It is one of the possible positional isomers of trimethoxyamphetamine and is a positional isomer of 3,4,5-trimethoxyamphetamine (TMA or TMA-1). [1] [2]
In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists 2,3,6-TMA's dose as approximately 30 mg or more orally and its duration as 8 to 10 hours. [1] [2] [3] [4] Based on limited testing, the effects of 2,3,6-TMA were reported to include intense introspection, mild stimulation, and pupil dilation, among others. [1] The drug was said to be comparable to about 75 μg or more LSD. [1] It is approximately 10 times more potent than mescaline. [1] [3] [4] However, it was noted that more testing was needed. [1]
Unlike the other TMA isomers, 2,3,6-TMA was not tested at serotonin receptors or in rodent drug discrimination tests. [5] [6] [7] [8]
The chemical synthesis of 2,3,6-TMA has been described. [1] [2]
2,3,6-TMA was first described in the scientific literature by Alexander Shulgin in 1966. [2] [9] Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). [2] [1]
As a positional isomer of 3,4,5-trimethoxyamphetamine (TMA), 2,3,6-TMA is a Schedule I controlled substance in the United States. [2]